Comparative pharmacokinetics and pharmacodynamics of the novel rapid- acting insulin analogue, insulin aspart, in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 55, Issue 3, 1999, Pages 199-203

  Home, P D ^a   Barriocanal, L ^a   Lindholm, A ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Insulin absorption; Insulin aspart; Rapid acting insulin analogue

Indexed keywords

INSULIN ASPART; INSULIN DERIVATIVE; NEUTRAL INSULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; INSULIN RELEASE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 0033060426     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050618     Document Type: Article

References (23)

1. 1. Brange J, Owens DR, Kang S, Vølund A (1990) Monomeric insulins and their experimental and clinical applications. Diabetes Care 13: 923-954
2. 2. Zinman B (1989) The physiological replacement of insulin: an elusive goal. New Engl J Med 321: 367-370
3. 3. Blundell T, Dodson G, Hodgkin D, Mercola D (1972) Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 26: 279-402
4. 4. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Sørensen AR, Voigt HO (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333: 679-682
5. 5. Ribel U (1993) Subcutaneous absorption of insulin analogues. Front Insulin Pharmacol: 70-78
6. 6. Vølund A, Brange J, Drejer K, Jensen I, Markussen J, Ribel U, Sørensen AR, Schlichtkrull J (1991) In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet Med 8: 839-847
7. 7. Drejer K, Kruse V, Larsen UD, Hougaard P, Soren B, Gammeltoft S (1991) Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40: 1488-1495
8. 8. Jensen I, Kruse V, Larsen UD (1991) Scintigraphic studies in rats. Kinetics of insulin analogues covering wide range of receptor affinities. Diabetes 40: 628-632
9. 9. Kang S, Brange J, Burch A, Vølund A, Owens DR (1991) Subcutaneous insulin absorption explained by insulin's physicochemical properties: evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 14: 942-948
10. 10. Heinemann L, Heise T, Jorgensen LN, Starke AAR (1993) Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med 10: 535-539
11. 11. Commission of the European Communities CPMP working party on efficacy of medical products (1990) Good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol 67: 361-372
12. 12. Owens DR (1986) Human insulin: clinical pharmacological studies in man. MTP Press, Lancaster, pp 137-139
13. 13. Veng-Pedersen V (1989) Mean time parameters in pharmacokinetics: definition, computation and clinical implications (parts 1 and 2). Clin Pharmacokinet 17: 345-366 and 424-440
14. 14. Kang S, Creagh FM, Ara J, Owens DR, Peters JR (1991) Insulin analogues and human insulin: near-equivalent in vivo biological activity in healthy males in spite of widely different in vitro potencies. Diabetes 40 [Suppl 1]: A969
15. 15. Dimitriadis GD, Gerich JE (1983) Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 6: 374-377
16. 16. Lean MEJ, Ng LL, Tennison BR (1985) Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. Br Med J 290: 105-108
17. 17. Jorgensen LN, Nielsen FS (1990) Timing of pre-meal insulins in diabetic patients on a multiple daily injection regimen: a questionnaire study. Diabetologia 33 [Suppl 1]: A116
18. 18. Eaton PR, Allen RC, Schade DS, Standefer JC (1980) Normal insulin secretion: the goal of artificial insulin delivery systems. Diabetes Care 3: 270-273
19. 19. Olsson PO, Arnqvist HJ, von Schenck HV (1988) Free insulin profiles during intensive treatment with biosynthetic human insulin. Diabete Metab 14: 253-258
20. 20. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. New Engl J Med 318: 1231-1239
21. 21. Heinemann L, Kapitza C, Starke AAR, Heise T (1996) Time-action profile of the insulin analogue B28Asp. Diabet Med 13: 683-687
22. 22. Kang S, Creagh FM, Peters JR, Brange J, Vølund A, Owens DR (1991) Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 14: 571-577
23. 23. Wiefels K, Hübinger A, Dannehl K, Gries FA (1995) Insulin-kinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp). Horm Metab Res 27: 421-424